View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 25, 2015

Ireland’s Medtronic to buy California medical device firm Twelve for $458m

Irish medical technology firm Medtronic has signed an agreement to acquire California-based medical device company, Twelve, in a cash and debt-free transaction valued at up to $458m.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.
Medtronic

Irish medical technology firm Medtronic has signed an agreement to acquire California-based medical device company, Twelve, in a cash and debt-free transaction valued at up to $458m.

Under the agreement, Medtronic will pay $408m at closing and $50m on achievement of CE Marking for Twelve’s transcatheter mitral valve replacement (TMVR) device.

Medtronic Coronary and Structural Heart president Sean Salmon said: "Upon close, this acquisition will strategically augment our existing capabilities in the transcatheter mitral space, which represents an important growth opportunity for Medtronic.

"The combined strengths of our organisations will significantly accelerate our ability to deliver an exciting and differentiated therapy to patients."

"We have followed the transcatheter mitral valve space closely and firmly believe that Twelve has the most novel technology along with a strong, proven team.

"The combined strengths of our organisations will significantly accelerate our ability to deliver an exciting and differentiated therapy to patients, physicians and healthcare systems around the world."

Currently under development, the TMVR device will be designed to treat patients with mitral valve regurgitation in whom standard restorative surgery is not recommended. The majority of such patients are said to be largely underserved with limited treatment options.

Mitral regurgitation occurs due to the failure of the heart’s mitral valve to close normally, which enables blood to flow backwards when the heart contracts. Over time, the condition leads to declining heart function and heart failure.

After the completion of transaction, Medtronic will manage Twelve’s product line as part of the Coronary and Structural Heart division within the Cardiac and Vascular Group. The TMVR device is yet to be authorised for sale in any country.

According to Medtronic, Twelve is the twelfth firm spun out from the medical device incubator The Foundry.

Subject to customary closing conditions, the transaction is anticipated to close in October this year.


Image: The world headquarters of Medtronic in Fridley, Minnesota, US. Photo: courtesy of Bobak Ha’Eri.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network